ME02643B - Formulacija i metod obložene tablete - Google Patents
Formulacija i metod obložene tableteInfo
- Publication number
- ME02643B ME02643B MEP-2016-213A MEP21316A ME02643B ME 02643 B ME02643 B ME 02643B ME P21316 A MEP21316 A ME P21316A ME 02643 B ME02643 B ME 02643B
- Authority
- ME
- Montenegro
- Prior art keywords
- coating layer
- coating
- tablet
- polymer
- coated tablet
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 8
- 238000009472 formulation Methods 0.000 title claims 7
- 238000000034 method Methods 0.000 title claims 3
- 239000011247 coating layer Substances 0.000 claims 23
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 12
- 229920001688 coating polymer Polymers 0.000 claims 12
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 12
- 239000004014 plasticizer Substances 0.000 claims 11
- 229920000642 polymer Polymers 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 7
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims 7
- 229960004937 saxagliptin Drugs 0.000 claims 7
- 108010033693 saxagliptin Proteins 0.000 claims 7
- 239000010410 layer Substances 0.000 claims 5
- 229940068196 placebo Drugs 0.000 claims 5
- 239000000902 placebo Substances 0.000 claims 5
- 239000011253 protective coating Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 238000001035 drying Methods 0.000 claims 3
- 230000001737 promoting effect Effects 0.000 claims 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 239000008199 coating composition Substances 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229960001021 lactose monohydrate Drugs 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (13)
1. Obložena tableta koja se sastoji od jezgra tablete i a) unutrašnjeg izolacionog oblažućeg sloja koji oblaže jezgro tablete, koji sadrži formulaciju oblažućeg polimera koja sadrži polimer na bazi polivinil alkohola (PVA) i plastifikator;b) drugog oblažućeg sloja koji sadrži lek obložen preko unutrašnjeg izolacionog oblažućeg sloja koji oblaže jezgro tablete, te drugi oblažući sloj sadrži saksagliptinili njegovu farmaceutski prihvatljivu so i formulaciju oblažućeg polimera koja sadrži polimer na bazi PVA i plastifikator; i c) spoljašnjeg zaštitnog oblažućeg sloja koji oblaže drugi oblažući sloj jezgra tablete, pri čemu pomenuti spoljašnji zaštitni oblažući sloj sadrži formulaciju oblažućeg sloja koja sadrži polimer na bazi PVA i plastifikator,te naznačena time da drugi oblažući sloj sadrži od 0.1 do 70% težinski leka i od 30 do 99.5% težinski oblažućeg polimera, bazirano na težini drugog oblažućeg sloja.
2. Obložena tableta prema patentnom zahtevu 1 naznačena time što formulacija oblažućeg polimera u drugom oblažućem sloju je bar oko 2 mg uz jezgro tablete od 200 mg, a saksagliptin ili njegova farmaceutski prihvatljiva so je bar oko 0.2 mg uz jezgro tablete od 200 mg.
3. Obložena tableta prema patentnom zahtevu 1 naznačena time što je polimer na bazi PVA u drugom oblažućem sloju identičan polimeru na bazi PVA u drugim oblažućim slojevima.
4. Obložena tableta prema patentnom zahtevu 1 naznačena time što se polimer na bazi PVA sastoji od polivinil alkohola.
5. Obložena tableta prema patentnom zahtevu 1 naznačena time što je u drugom oblažućem sloju saksagliptin ili njemu farmaceutski odgovarajuća so prisutna u količini unutar raspona od 0,2 do 140 mg a oblažući polimer je prisutan u količini unutar raspona od 2 do 140 mg, i u svakom unutrašnjem izolacionom oblažućem sloju i spoljašnjem zaštitnom oblažućem sloju, oblažući polimer je prisutan u količini u granicama od oko 1 do oko 100 mg.
6. Obložena tableta prema patentnom zahtevu 1 naznačena time što je jezgro tablete sastavljeno od jednog ili više rastvarača i opciono jednog ili više podmazivača tablete.
7. Obložena tableta prema patentnom zahtevu 6 naznačena time što se jezgro tablete sastoji od mikrokristalne celuloze, laktoza monohidrata, kroskarmeloza natrijuma i magnezijum stearata.
8. Obložena tableta prema patentnom zahtevu 1, naznačena time što se drugi oblažući sloj sastoji od plastifikatora.
9. Obložena tableta prema patentnom zahtevu 8, naznačena time što je početna tableta drugi lek u obliku tablete.
10. Obložena tableta prema patentnom zahtevu 1 koja ima sledeći sastav: Materijal placebo tablete Raspon % težine placebo jezgra tablete od 200 mg Laktoza 20 do 75%/40 do 150 mg Mikrokristalna celuloza 20 do 75%/40 do 150 mg Kroskarmeloza natrijum 2 do 10%/4 do 20 mg Magnezijum stearat 0,2 do 2%/0,4 do 4 mg Prvi unutrašnji izolacioni oblažući sloj % težine placebo jezgra tablete od 200 mg Oblažući polimer, i opciono plastifikator i opciono agensi koji podstiču protočnost 1 do 3%/2 do 6 mg Drugi oblažući sloj % težine placebo jezgra tablete od 200 mg saksagliptin (slobodna baza ili HCL so) 0,25 do 70%/0,5 do 140 mg Oblažući polimer, i opciono plastifikator i opciono agensi koji podstiču protočnost 1 do 50%/2 do 100 mg Treći spoljašnji zaštitni oblažući sloj % težine placebo jezgra tablete od 200 mg Oblažući polimer, i opciono plastifikator i opciono agensi koji podstiču protočnost i boja 1 do 5%/2 do 10 mg
11. Obložena tableta kao što je definisano u zahtevu 1 naznačena time što se za snagu od 5 mg drugi oblažući sloj sastoji od 5 mg saksagliptina ili njegove farmaceutski prihvatljive soli i 5 mg oblažućeg sloja koji je baziran na polimeru i za snagu od 2.5 mg oblažući sloj se sastoji od 2.5 mg saksagliptina ili njegove farmaceutski prihvatljive soli i 20 mg oblažućeg sloja koji je baziran na polimeru.
12. Metod za pripremanje obložene tablete prema patentnom zahtevu 1 obuhvata sledeće: a) obezbeđivanje jezgra tablete; b) obložena tableta sa formulacijom unutrašnjeg izolacionog oblažućeg sloja koja obuhvata bar jedan polimer koji je baziran na PVA i plastifikator; c) sušenje obložene tablete radi formiranja unutrašnjeg izolacionog sloja na njoj; d) oblaganje tako obložene tablete sa formulacijom drugog oblažućeg sloja koja obuhvata lek koji je saksagliptin ili njegova farmaceutski prihvatljiva so i bar jedan oblažući polimer baziran na PVA i plastifikator; e) sušenje tako obložene tablete radi formiranja drugog oblažućeg sloja na njoj; i f) oblaganje tako obložene tablete sa formulacijom trećeg spoljašnjeg zaštitnog oblažućeg sloja koja sadrži bar jedan oblažući polimer baziran na PVA i plastifikator; i g) sušenje tako obložene tablete radi formiranja obložene tablete pronalaska.
13. Postupak kao što je definisano u patentnom zahtevu 12, naznačen time što se slojevi za oblaganje primenjuju kao suspenzija polimera za oblaganje koji je baziran na PVA i plastifikatora. 4
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57531904P | 2004-05-28 | 2004-05-28 | |
| EP10179007.9A EP2298288B2 (en) | 2004-05-28 | 2005-05-26 | Coated tablet formulation and method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02643B true ME02643B (me) | 2017-06-20 |
Family
ID=34971747
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-145A ME02516B (me) | 2004-05-28 | 2005-05-26 | Formulacija i metod obložene tablete |
| MEP-2016-213A ME02643B (me) | 2004-05-28 | 2005-05-26 | Formulacija i metod obložene tablete |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-145A ME02516B (me) | 2004-05-28 | 2005-05-26 | Formulacija i metod obložene tablete |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US7951400B2 (me) |
| EP (3) | EP2298288B2 (me) |
| JP (1) | JP4901727B2 (me) |
| KR (2) | KR101290925B1 (me) |
| CN (2) | CN102895208B (me) |
| AR (2) | AR049062A1 (me) |
| AU (1) | AU2005249467B2 (me) |
| BR (1) | BRPI0510419B8 (me) |
| CA (1) | CA2568391C (me) |
| CY (2) | CY1117813T1 (me) |
| DK (2) | DK1753406T4 (me) |
| ES (3) | ES2582646T5 (me) |
| GE (1) | GEP20094639B (me) |
| HR (2) | HRP20160880T4 (me) |
| HU (2) | HUE029446T2 (me) |
| IL (2) | IL179454A (me) |
| LT (1) | LT2298288T (me) |
| ME (2) | ME02516B (me) |
| MX (1) | MXPA06013711A (me) |
| MY (1) | MY147639A (me) |
| NO (1) | NO343907B1 (me) |
| NZ (1) | NZ551591A (me) |
| PE (1) | PE20060425A1 (me) |
| PH (1) | PH12013500450A1 (me) |
| PL (2) | PL1753406T5 (me) |
| PT (2) | PT2298288T (me) |
| RS (2) | RS54929B2 (me) |
| RU (1) | RU2372894C2 (me) |
| SI (3) | SI1753406T2 (me) |
| TW (2) | TWI415635B (me) |
| UA (1) | UA88168C2 (me) |
| WO (1) | WO2005117841A1 (me) |
| ZA (1) | ZA200609541B (me) |
Families Citing this family (129)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0487425A (ja) * | 1990-07-31 | 1992-03-19 | Fujitsu Ltd | 回線切り替え装置 |
| EP1368349B1 (de) * | 2001-02-24 | 2007-02-14 | Boehringer Ingelheim Pharma GmbH & Co.KG | Xanthinderivate, deren herstellung und deren verwendung als arzneimittel |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| AU2005210285B2 (en) | 2004-02-05 | 2008-01-24 | Kyorin Pharmaceutical Co., Ltd. | Bicycloester derivative |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| TW200534879A (en) * | 2004-03-25 | 2005-11-01 | Bristol Myers Squibb Co | Coated tablet formulation and method |
| US7829720B2 (en) * | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
| US20050256314A1 (en) * | 2004-05-04 | 2005-11-17 | Soojin Kim | Process employing controlled crystallization in forming crystals of a pharmaceutical |
| TWI415635B (zh) | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | 加衣錠片調製物及製備彼之方法 |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| GB0526291D0 (en) * | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
| CA2635841A1 (en) * | 2006-02-09 | 2007-08-16 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical formulations of montelukast sodium |
| EP1995237A4 (en) * | 2006-03-08 | 2011-07-06 | Kyorin Seiyaku Kk | PROCESS FOR PREPARING AN AMINOACETYLPYRROLIDINCARBONITRILE DERIVATIVE AND PRODUCTION PRODUCT THEREOF |
| EP2540725A1 (de) | 2006-05-04 | 2013-01-02 | Boehringer Ingelheim International GmbH | Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP1852108A1 (en) * | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| US20080064701A1 (en) * | 2007-04-24 | 2008-03-13 | Ramesh Sesha | Anti-diabetic combinations |
| US20070172525A1 (en) * | 2007-03-15 | 2007-07-26 | Ramesh Sesha | Anti-diabetic combinations |
| TW200904405A (en) | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Pharmaceutical formulations containing an SGLT2 inhibitor |
| WO2008114857A1 (ja) * | 2007-03-22 | 2008-09-25 | Kyorin Pharmaceutical Co., Ltd. | アミノアセチルピロリジンカルボニトリル誘導体の製造方法 |
| PE20090696A1 (es) | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
| DE602008005316D1 (de) * | 2007-06-22 | 2011-04-14 | Bristol Myers Squibb Co | Tablettierte atazanavirhaltige zusammensetzungen |
| MX2009013499A (es) * | 2007-06-22 | 2010-01-18 | Bristol Myers Squibb Co | Composiciones comprimidas que contienen atazanavir. |
| CN101778624A (zh) * | 2007-06-22 | 2010-07-14 | 百时美施贵宝公司 | 含有阿扎那韦的压片组合物 |
| JP2010530892A (ja) * | 2007-06-22 | 2010-09-16 | ブリストル−マイヤーズ スクイブ カンパニー | アタザナビルを含む錠剤組成物 |
| CN101772304B (zh) * | 2007-07-31 | 2014-07-09 | 卡吉尔公司 | 直接可压缩的右旋糖 |
| AU2008286914B2 (en) * | 2007-08-13 | 2014-10-02 | Ohemo Life Sciences Inc. | Abuse resistant drugs, method of use and method of making |
| CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
| US8551524B2 (en) * | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| IT1393244B1 (it) * | 2008-07-18 | 2012-04-12 | Universita' Degli Studi Di Milano | Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| WO2010016584A1 (ja) * | 2008-08-07 | 2010-02-11 | 杏林製薬株式会社 | ビシクロ[２．２．２]オクチルアミン誘導体の製造方法 |
| CA2734075C (en) * | 2008-08-12 | 2017-04-18 | Inspirion Delivery Technologies, Llc | Pharmaceutical compositions configured to deter dosage form splitting |
| KR20110044780A (ko) * | 2008-08-14 | 2011-04-29 | 교린 세이야꾸 가부시키 가이샤 | 안정화된 의약 조성물 |
| NZ604091A (en) | 2008-08-15 | 2014-08-29 | Boehringer Ingelheim Int | Purin derivatives for use in the treatment of fab-related diseases |
| CN102149407A (zh) | 2008-09-10 | 2011-08-10 | 贝林格尔.英格海姆国际有限公司 | 治疗糖尿病和相关病症的组合疗法 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| DE102008059206A1 (de) | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
| CN102256976A (zh) | 2008-12-23 | 2011-11-23 | 贝林格尔.英格海姆国际有限公司 | 有机化合物的盐形式 |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
| JP5685550B2 (ja) | 2009-02-13 | 2015-03-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用 |
| AU2010212823B2 (en) | 2009-02-13 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| CN102438617A (zh) | 2009-03-27 | 2012-05-02 | 杏林制药株式会社 | 含有碱性添加剂的基质型缓释制剂 |
| MX2011009852A (es) | 2009-03-27 | 2011-09-29 | Bristol Myers Squibb Co | Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv. |
| KR20120006047A (ko) * | 2009-04-09 | 2012-01-17 | 산도즈 아게 | 삭사글립틴의 결정 형태 |
| ES2689107T3 (es) | 2009-11-13 | 2018-11-08 | Astrazeneca Ab | Formulaciones de tabletas bicapa |
| EP2498759B1 (en) | 2009-11-13 | 2018-08-01 | AstraZeneca AB | Immediate release tablet formulations |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| EP2547339A1 (en) | 2010-03-18 | 2013-01-23 | Boehringer Ingelheim International GmbH | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| CN102210693B (zh) * | 2010-04-10 | 2013-10-09 | 山东新华制药股份有限公司 | 一种阿司匹林和双嘧达莫多层片的制备方法 |
| CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
| CN103140475A (zh) | 2010-05-05 | 2013-06-05 | 亚细亚化学工业有限公司 | 沙格列汀中间体,沙格列汀多晶型物,及其制备方法 |
| WO2011161161A1 (en) | 2010-06-24 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
| EP2601175A1 (en) | 2010-08-06 | 2013-06-12 | Sandoz AG | A novel crystalline compound comprising saxagliptin and phosphoric acid |
| EP2601176A1 (en) | 2010-08-06 | 2013-06-12 | Sandoz AG | Novel salts of saxagrliptin with organic di-acids |
| EP2611442B1 (en) | 2010-09-03 | 2018-07-04 | Bristol-Myers Squibb Company | Drug formulations using water soluble antioxidants |
| EP2608788A1 (en) | 2010-10-04 | 2013-07-03 | Assia Chemical Industries Ltd. | Polymorphs of saxagliptin hydrochloride and processes for preparing them |
| ES2687027T3 (es) | 2010-11-04 | 2018-10-23 | Albireo Ab | Inhibidores de ibat para el tratamiento de enfermedades hepáticas |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| CN102086172A (zh) * | 2011-01-13 | 2011-06-08 | 廖国超 | 沙格列汀的药用盐及其制备方法 |
| BR112013019026A2 (pt) * | 2011-02-01 | 2016-10-04 | Astrazeneca Uk Ltd | formulações farmacêuticas incluindo um composto amina |
| US8883800B2 (en) | 2011-07-15 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| WO2013024036A1 (en) | 2011-08-12 | 2013-02-21 | Boehringer Ingelheim Vetmedica Gmbh | Funny current (if) inhibitors for use in a method of treating and preventing heart failure in feline |
| EP2753328A1 (en) | 2011-09-07 | 2014-07-16 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dpp-iv inhibitor formulations |
| US9446000B2 (en) | 2011-09-08 | 2016-09-20 | Masdar Institute Of Science And Technology | Cellulosic gel material as a pharmaceutical excipient |
| EP2578208B1 (en) | 2011-10-06 | 2014-05-21 | Sanovel Ilac Sanayi ve Ticaret A.S. | DPP-IV inhibitor solid dosage formulations |
| WO2013106526A1 (en) | 2012-01-10 | 2013-07-18 | Teva Pharmaceutical Industries Ltd. | Saxagliptin parmaceutical formulations |
| US10973768B2 (en) | 2012-03-01 | 2021-04-13 | Bristol-Myers Squibb Company | Extended release pharmaceutical formulations of water-soluble active pharmaceutical ingredients and methods for making the same |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| IN2014DN09045A (me) | 2012-05-07 | 2015-05-22 | Bayer Pharma AG | |
| JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| JP6218811B2 (ja) | 2012-05-14 | 2017-10-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2013179307A2 (en) * | 2012-05-29 | 2013-12-05 | Mylan Laboratories Limited | Stabilized pharmaceutical compositions of saxagliptin |
| WO2014030051A1 (en) | 2012-08-23 | 2014-02-27 | Aurobindo Pharma Limited | Stable pharmaceutical compositions comprising saxagliptin |
| JP6283316B2 (ja) * | 2012-10-26 | 2018-02-21 | 株式会社三和化学研究所 | アナグリプチン含有固形製剤 |
| WO2014096983A1 (en) | 2012-12-21 | 2014-06-26 | Wockhardt Limited | Stable pharmaceutical compositions of saxagliptin or salts thereof |
| WO2014096982A1 (en) | 2012-12-21 | 2014-06-26 | Wockhardt Limited | Stable pharmaceutical compositions of saxagliptin or salts thereof |
| US20140275149A1 (en) | 2013-03-15 | 2014-09-18 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
| WO2014193528A1 (en) * | 2013-04-29 | 2014-12-04 | Anovel Pharmaceuticals, Llc | Amorphous dosage forms and methods |
| CN103316056B (zh) * | 2013-06-24 | 2015-07-08 | 江苏鹏鹞药业有限公司 | 一种板蓝根包衣分散片及其制备方法 |
| WO2015071887A1 (en) | 2013-11-18 | 2015-05-21 | Ranbaxy Laboratories Limited | Oral pharmaceutical compositions of saxagliptin |
| WO2015071889A1 (en) | 2013-11-18 | 2015-05-21 | Ranbaxy Laboratories Limited | Oral compositions of saxagliptin |
| MX378845B (es) * | 2014-01-21 | 2025-03-10 | Bpsi Holdings Llc | Revestimientos de pelicula de liberacion inmediata que contienen gliceridos de cadena media y sustratos revestidos con los mismos. |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| CN106659726A (zh) * | 2014-06-25 | 2017-05-10 | Ea制药株式会社 | 固体制剂及其着色防止或着色减少方法 |
| US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
| CN105520913B (zh) * | 2014-09-28 | 2020-06-23 | 石药集团中奇制药技术（石家庄）有限公司 | 一种包含沙格列汀的微丸、其用途及其制备方法 |
| CN105497023B (zh) * | 2014-10-15 | 2021-05-25 | 北京福元医药股份有限公司 | 一种沙格列汀药物制剂 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| CN104557943B (zh) * | 2014-12-23 | 2017-05-03 | 扬子江药业集团四川海蓉药业有限公司 | 一种维格列汀杂质的制备方法 |
| CN105796503B (zh) * | 2014-12-30 | 2019-05-07 | 深圳翰宇药业股份有限公司 | 一种沙格列汀微丸及其制剂 |
| CN104672243B (zh) * | 2015-02-10 | 2017-09-22 | 华润赛科药业有限责任公司 | 维格列汀降解杂质的制备方法 |
| HK1247105A1 (zh) | 2015-04-02 | 2018-09-21 | Theravance Biopharma R&D Ip, Llc | Mu类鸦片受体拮抗剂与类鸦片药剂的组合剂型 |
| CN106176661B (zh) * | 2015-04-29 | 2019-02-01 | 四川科伦药物研究院有限公司 | 一种沙格列汀或其盐的胶囊及其制备方法 |
| SI3881833T1 (sl) * | 2015-06-30 | 2024-03-29 | Genentech, Inc., | Tablete s takojšnjim sproščanjem, ki vsebujejo zdravilo in postopek za oblikovanje tablet |
| CN106924207A (zh) * | 2015-12-31 | 2017-07-07 | 深圳翰宇药业股份有限公司 | 一种维格列汀片剂及其制备方法 |
| ES2874669T3 (es) | 2016-02-09 | 2021-11-05 | Albireo Ab | Formulación oral de colestiramina y uso de la misma |
| WO2017138878A1 (en) | 2016-02-09 | 2017-08-17 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| CN108601739B (zh) | 2016-02-09 | 2022-01-04 | 阿尔比里奥公司 | 考来烯胺丸剂及其制备方法 |
| CN109310697A (zh) | 2016-06-10 | 2019-02-05 | 勃林格殷格翰国际有限公司 | 利格列汀和二甲双胍的组合 |
| CN111032019B (zh) | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | 考来烯胺颗粒、口服考来烯胺制剂及其用途 |
| CN108822820B (zh) * | 2018-05-22 | 2020-11-03 | 东莞理工学院 | 一种隔离型水合物动力学抑制胶囊及其制备方法与应用 |
| CN112449637B (zh) | 2018-06-05 | 2024-03-19 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| PL3810581T3 (pl) | 2018-06-20 | 2025-04-28 | Albireo Ab | Modyfikacje kryształu odewiksibatu |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| WO2020098904A1 (en) | 2018-11-12 | 2020-05-22 | Pharmaceutical Oriented Services Ltd | Dosage form containing metformin and a dipeptidyl peptidase iv inhibitor |
| CN118852054A (zh) | 2019-02-06 | 2024-10-29 | 阿尔比里奥公司 | 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途 |
| TWI835997B (zh) | 2019-02-06 | 2024-03-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻氮呯化合物及其用作膽酸調節劑之用途 |
| CN109999006A (zh) * | 2019-04-28 | 2019-07-12 | 江苏豪森药业集团有限公司 | 沙格列汀包衣片及其制备方法 |
| ES2973355T3 (es) | 2019-12-04 | 2024-06-19 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
| JP7696898B2 (ja) | 2019-12-04 | 2025-06-23 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| IL293379B2 (en) | 2019-12-04 | 2026-04-01 | Albireo Ab | Benzothia(dia)azepine compounds and their use as bile acid modulators |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| EP4069247B1 (en) | 2019-12-04 | 2025-03-26 | Albireo AB | Benzothiadiazepine compounds and their use as bile acid modulators |
| JP7514121B2 (ja) | 2020-06-23 | 2024-07-10 | 沢井製薬株式会社 | サキサグリプチン含有製剤及びその製造方法 |
| EP4188541B1 (en) | 2020-08-03 | 2024-12-25 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CA3196488A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| BR112023010799A2 (pt) | 2020-12-04 | 2023-10-03 | Albireo Ab | Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares |
| JP2022135147A (ja) * | 2021-03-04 | 2022-09-15 | 日医工株式会社 | サキサグリプチン含有錠剤 |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| KR20220165346A (ko) | 2021-06-08 | 2022-12-15 | 동아에스티 주식회사 | 에보글립틴의 안정성이 개선된 제제 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3696188A (en) * | 1971-06-16 | 1972-10-03 | Schering Corp | Laminated tablets |
| DE3403329A1 (de) * | 1984-02-01 | 1985-08-01 | Horst Dr. 4019 Monheim Zerbe | Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe |
| JPS6186211A (ja) | 1984-10-04 | 1986-05-01 | 日本碍子株式会社 | セラミックス複合構造体及びその製造法 |
| FR2623810B2 (fr) * | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
| US5158777A (en) * | 1990-02-16 | 1992-10-27 | E. R. Squibb & Sons, Inc. | Captopril formulation providing increased duration of activity |
| CA2068402C (en) * | 1991-06-14 | 1998-09-22 | Michael R. Hoy | Taste mask coatings for preparation of chewable pharmaceutical tablets |
| US5428048A (en) | 1993-11-08 | 1995-06-27 | American Home Products Corporation | Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents |
| GB9407386D0 (en) * | 1994-04-14 | 1994-06-08 | Smithkline Beecham Plc | Pharmaceutical formulation |
| TW483763B (en) * | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
| US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
| TW522014B (en) | 1997-02-07 | 2003-03-01 | Sepracor Inc | Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine |
| GB9715896D0 (en) | 1997-07-28 | 1997-10-01 | Sca Packaging Ltd | Containers |
| US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
| US20010055613A1 (en) * | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
| AU765128B2 (en) * | 1999-03-22 | 2003-09-11 | Bristol-Myers Squibb Company | Fused pyridopyridazine inhibitors of cGMP phosphodiesterase |
| US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| EP1243266A4 (en) | 1999-11-11 | 2007-03-07 | Kyorin Seiyaku Kk | SOLIDS PREPARATION FOR ORAL APPLICATION |
| US6569456B2 (en) * | 2000-01-13 | 2003-05-27 | Osmotica Corp. | Osmotic device containing diltiazem and an ACE inhibitor or diuretic |
| EP1743655B1 (en) * | 2000-01-21 | 2014-06-25 | Novartis AG | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| US6254888B1 (en) * | 2000-01-28 | 2001-07-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for coating pharmaceutical dosage forms |
| US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| IL145106A0 (en) | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| US6670344B2 (en) * | 2000-09-14 | 2003-12-30 | Bristol-Myers Squibb Company | Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts |
| US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| US6670334B2 (en) | 2001-01-05 | 2003-12-30 | University Of Virginia Patent Foundation | Method and compositions for treating the inflammatory response |
| AU2002248792B2 (en) | 2001-04-18 | 2006-09-21 | Nostrum Pharmaceuticals Inc. | A novel coating for a sustained release pharmaceutical composition |
| US20030035839A1 (en) * | 2001-05-15 | 2003-02-20 | Peirce Management, Llc | Pharmaceutical composition for both intraoral and oral administration |
| AU2003201071A1 (en) | 2002-01-15 | 2003-07-30 | Ranbaxy Laboratories Limited | Stable pharmaceutical compositions comprising ace inhibitor(s) |
| KR100456833B1 (ko) | 2002-08-01 | 2004-11-10 | 주식회사 대웅 | 아목시실린 및 클라불라네이트를 함유하는 유핵정 |
| US7670624B2 (en) * | 2004-01-29 | 2010-03-02 | Astella Pharma Inc. | Gastrointestinal-specific multiple drug release system |
| TW200534879A (en) * | 2004-03-25 | 2005-11-01 | Bristol Myers Squibb Co | Coated tablet formulation and method |
| US7829720B2 (en) * | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
| US20050256314A1 (en) * | 2004-05-04 | 2005-11-17 | Soojin Kim | Process employing controlled crystallization in forming crystals of a pharmaceutical |
| US20050288343A1 (en) * | 2004-05-19 | 2005-12-29 | Andrew Rusowicz | Process of preparing substituted carbamates and intermediates thereof |
| TWI415635B (zh) | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | 加衣錠片調製物及製備彼之方法 |
-
2005
- 2005-05-23 TW TW100134799A patent/TWI415635B/zh not_active IP Right Cessation
- 2005-05-23 TW TW094116772A patent/TWI354569B/zh not_active IP Right Cessation
- 2005-05-24 RS RS20160563 patent/RS54929B2/sr unknown
- 2005-05-25 US US11/137,068 patent/US7951400B2/en active Active
- 2005-05-26 WO PCT/US2005/018692 patent/WO2005117841A1/en not_active Ceased
- 2005-05-26 ME MEP-2016-145A patent/ME02516B/me unknown
- 2005-05-26 SI SI200532082T patent/SI1753406T2/sl unknown
- 2005-05-26 CA CA2568391A patent/CA2568391C/en not_active Expired - Fee Related
- 2005-05-26 DK DK05756474T patent/DK1753406T4/da active
- 2005-05-26 PL PL05756474T patent/PL1753406T5/pl unknown
- 2005-05-26 HR HRP20160880TT patent/HRP20160880T4/hr unknown
- 2005-05-26 KR KR1020067024818A patent/KR101290925B1/ko not_active Expired - Lifetime
- 2005-05-26 ES ES05756474T patent/ES2582646T5/es not_active Expired - Lifetime
- 2005-05-26 RU RU2006146971/15A patent/RU2372894C2/ru active
- 2005-05-26 JP JP2007515382A patent/JP4901727B2/ja not_active Expired - Lifetime
- 2005-05-26 EP EP10179007.9A patent/EP2298288B2/en not_active Expired - Lifetime
- 2005-05-26 PH PH1/2013/500450A patent/PH12013500450A1/en unknown
- 2005-05-26 CN CN201210377942.2A patent/CN102895208B/zh not_active Expired - Lifetime
- 2005-05-26 HU HUE10179007A patent/HUE029446T2/en unknown
- 2005-05-26 ME MEP-2016-213A patent/ME02643B/me unknown
- 2005-05-26 MY MYPI20052400A patent/MY147639A/en unknown
- 2005-05-26 NZ NZ551591A patent/NZ551591A/en not_active IP Right Cessation
- 2005-05-26 RS RS20160797A patent/RS55174B2/sr unknown
- 2005-05-26 LT LTEP10179007.9T patent/LT2298288T/lt unknown
- 2005-05-26 KR KR1020127014475A patent/KR20120064141A/ko not_active Ceased
- 2005-05-26 BR BRPI0510419A patent/BRPI0510419B8/pt not_active IP Right Cessation
- 2005-05-26 CN CN2005800245879A patent/CN1988891B/zh not_active Expired - Lifetime
- 2005-05-26 MX MXPA06013711A patent/MXPA06013711A/es active IP Right Grant
- 2005-05-26 AU AU2005249467A patent/AU2005249467B2/en not_active Expired
- 2005-05-26 HU HUE05756474A patent/HUE029039T2/en unknown
- 2005-05-26 ES ES10179007T patent/ES2593582T5/es not_active Expired - Lifetime
- 2005-05-26 DK DK10179007.9T patent/DK2298288T4/da active
- 2005-05-26 GE GEAP20059797A patent/GEP20094639B/en unknown
- 2005-05-26 PT PT101790079T patent/PT2298288T/pt unknown
- 2005-05-26 UA UAA200613939A patent/UA88168C2/uk unknown
- 2005-05-26 EP EP16166031.1A patent/EP3078369B1/en not_active Expired - Lifetime
- 2005-05-26 ES ES16166031T patent/ES2754573T3/es not_active Expired - Lifetime
- 2005-05-26 EP EP05756474.2A patent/EP1753406B2/en not_active Expired - Lifetime
- 2005-05-26 SI SI200532082A patent/SI1753406T1/sl unknown
- 2005-05-26 SI SI200532097T patent/SI2298288T2/sl unknown
- 2005-05-26 PL PL10179007T patent/PL2298288T5/pl unknown
- 2005-05-26 PT PT05756474T patent/PT1753406E/pt unknown
- 2005-05-27 AR ARP050102188A patent/AR049062A1/es not_active Application Discontinuation
- 2005-05-30 PE PE2005000601A patent/PE20060425A1/es active IP Right Grant
-
2006
- 2006-11-16 ZA ZA2006/09541A patent/ZA200609541B/en unknown
- 2006-11-21 IL IL179454A patent/IL179454A/en active IP Right Grant
- 2006-12-15 NO NO20065870A patent/NO343907B1/no unknown
-
2011
- 2011-04-26 US US13/094,379 patent/US8628799B2/en not_active Expired - Fee Related
-
2012
- 2012-02-14 IL IL218117A patent/IL218117A/en active IP Right Grant
-
2014
- 2014-01-08 US US14/150,331 patent/US9339472B2/en not_active Expired - Lifetime
- 2014-05-22 US US14/284,840 patent/US20140255486A1/en not_active Abandoned
-
2015
- 2015-02-24 AR ARP150100554A patent/AR099567A2/es unknown
-
2016
- 2016-07-19 CY CY20161100703T patent/CY1117813T1/el unknown
- 2016-09-21 HR HRP20161210TT patent/HRP20161210T4/hr unknown
- 2016-09-22 CY CY20161100945T patent/CY1118162T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02643B (me) | Formulacija i metod obložene tablete | |
| JP2008501025A5 (me) | ||
| CA2724533C (en) | Stabilized atypical antipsychotic formulation | |
| Conte et al. | Modulation of the dissolution profiles from Geomatrix® multi-layer matrix tablets containing drugs of different solubility | |
| CA2578626A1 (en) | Modified-release formulations of a bupropion salt | |
| US20070098746A1 (en) | Multi-layered coating technology for taste masking | |
| ES2200832T3 (es) | Formulacion de bupropion de liberacion controlada. | |
| AU2008324466A1 (en) | Sustained release tablets with hydromorphone | |
| JP2011510024A5 (me) | ||
| HRP20251291T1 (hr) | Formulacije (+)-2-[1-(3-etoksi-4-metoksi-fenil)-2-metansulfonil-etil]-4-acetil aminoizoindolin-1,3-diona | |
| KR20110126761A (ko) | 비구아나이드와 티아졸리디네디온 유도체를 함유하는 새로운 약제학적 제형 | |
| RU2005108609A (ru) | Лекарственные формы с модифицированным высвобождением, имеющие два ядра и отверстие | |
| AU2008306846B2 (en) | Mechanical protective layer for solid dosage forms | |
| WO2008023390B1 (en) | Modified release pharmaceutical composition of bupropion hydrochloride | |
| JP5822758B2 (ja) | 速溶性防湿フィルムコーティング製剤及びその製造方法 | |
| JP2015137238A (ja) | イブプロフェン及びトラネキサム酸を含有するフィルムコーティング製剤 | |
| JP2016516031A5 (me) | ||
| Khatavkar et al. | Novel approaches for development of oral controlled release compositions of galantamine hydrobromide and paroxetine hydrochloride hemihydrate: A review | |
| JP2020132600A (ja) | フィルムコーティング錠剤、およびその製造方法 | |
| KR101345468B1 (ko) | 졸피뎀 정제 | |
| JPH07252139A (ja) | 被覆軟カプセル剤 | |
| KR101137466B1 (ko) | 염산 알푸조신 함유 서방성 정제 | |
| TH75893A (th) | สูตรผสมยาเม็ดเคลือบและวิธี | |
| TH43293B (th) | สูตรผสมยาเม็ดเคลือบและวิธี | |
| WO2017222488A1 (en) | Sustained release formulation comprising tizanidine |